logo

Nektar Therapeutics (NKTR)



Trade NKTR now with
  Date
  Headline
9/21/2017 4:40:06 PM Nektar Therapeutics Appoints Jeff Ajer To Board Of Directors
9/20/2017 7:26:12 AM Nektar Therapeutics Reports Seven Abstracts Accepted For Presentation At 2017 SITC 32nd Annual Meeting
9/12/2017 9:04:14 AM Nektar Therapeutics Begins PROPEL Study To Evaluate Combination Of NKTR-214 With TECENTRIQ
8/8/2017 4:13:06 PM Nektar Therapeutics Q2 Loss Per Share $0.39 Vs Loss $0.36 Last Year
7/24/2017 7:31:01 AM Lilly And Nektar Therapeutics Announce Alliance To Develop And Commercialize NKTR-358
7/18/2017 8:03:18 AM Nektar Announces Topline Data From Human Abuse Potential Study For NKTR-181
7/10/2017 9:02:08 AM Nektar Presents New Preclinical Data For NKTR-358, A First-in-Class Regulatory T Cell Stimulator
6/26/2017 7:20:18 AM William Blair Reiterates Nektar Therapeutics (NKTR) At Outperform
5/9/2017 4:12:38 PM Nektar Therapeutics Q1 Loss/share $0.42 Vs. Loss $0.14 Year Ago
5/3/2017 9:15:45 AM Nektar Therapeutics Appoints Brian Kotzin As Head Of Clinical Development For Immunology Program
4/4/2017 9:05:40 AM Nektar Announces Five Preclinical Data Presentations For Immuno-oncology Programs Made AACR Annual Meeting 2017
3/27/2017 9:01:48 AM Nektar Initiates Clinical Study Of NKTR-358 Being Developed For Treatment Of Immune And Inflammatory Disorders